Harvard Health Blog

The very high cost of very low cholesterol

Posted November 13, 2015, 8:00 am Gregory Curfman, M.D., Editor in Chief, Harvard Health Publications You have probably heard about the new cholesterol-lowering drugs Praluent and Repatha, approved by the FDA within the last few weeks. Maybe you’ve even begun taking one of them yourself. These drugs are miraculous in their ability to lower LDL (low-density lipoprotein cholesterol), the type that leads to heart disease. But this power comes at a great price …

To continue reading this article you must be registered.

Get Licensed Content to Harvard Health

If you are interested in licensing content from Harvard Health Publications, please contact us using our online form. Our licensing and business development professionals will help you leverage consumer health content from Harvard Medical School as a clear differentiator in helping achieve your business goals.

Contact Us

Customer Log In